Covid-19 roundup: In fifth open let­ter, Daniel O’Day touts in­halant remde­sivir, promis­es 2M dos­es by year's end; Mer­ck’s an­tivi­ral moves in­to PhII

Since remde­sivir be­gan cap­tur­ing treat­ment hopes ear­ly in the out­break, one clear fac­tor has lim­it­ed its po­ten­tial: An­tivi­rals are known to work best in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER